US Stock MarketDetailed Quotes

TSHA Taysha Gene Therapies

Watchlist
  • 2.4550
  • -0.1550-5.94%
Close Dec 4 16:00 ET
  • 2.4600
  • +0.0050+0.20%
Post 20:01 ET
503.14MMarket Cap3.90P/E (TTM)

About Taysha Gene Therapies Company

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Company Profile

SymbolTSHA
Company NameTaysha Gene Therapies
Listing DateSep 24, 2020
Issue Price20.00
Founded2019
CEOMr. Sean P. Nolan
MarketNASDAQ
Employees52
Fiscal Year Ends12-31
Address3000 Pegasus Park Drive,Suite 1430
CityDallas
ProvinceTexas
CountryUnited States of America
Zip Code75247
Phone1-214-612-0000

Company Executives

  • Name
  • Position
  • Salary
  • Sean P. Nolan
  • Chairman of the Board and Chief Executive Officer
  • 1.52M
  • Kamran Alam, C.P.A.
  • Chief Financial Officer and Principal Accounting Officer
  • 975.40K
  • Dr. Sukumar Nagendran, M.D.
  • Director, President and Head of Research and Development
  • 1.25M
  • Alison S. Long
  • Independent Director
  • 77.96K
  • Sean Stalfort
  • Independent Director
  • 35.09K
  • Phillip B. Donenberg
  • Independent Director
  • 73.82K
  • Dr. Laura Sepp-Lorenzino, PhD
  • Independent Director
  • 76.90K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data